Ketamine Spray Therapy: How It Works and Who It Helps

What Is Ketamine Spray Therapy?

Ketamine spray therapy involves administering esketamine as a nasal spray. The medication, marketed as Spravato, is the only FDA-approved version of this treatment and must be given in certified clinics under supervision.

FDA-Approved Esketamine (Spravato)

Spravato marked a milestone as the first ketamine-based nasal treatment to receive FDA approval. This recognition confirmed ketamine’s role in mental health care beyond anesthesia. Patients benefit from standardized dosing and regulated safety protocols.

Clinic-Based Administration

During a session, patients self-administer the nasal spray under the guidance of medical professionals. They remain in the clinic for two hours afterward to allow staff to monitor vital signs and ensure a safe recovery.

Differences from Compounded Nasal Sprays

Some providers may offer compounded nasal sprays, but these are not FDA-approved and can vary in strength or consistency. At Community Minds, only regulated and approved Spravato treatment is provided for safety and effectiveness.

How This Treatment Works

The effectiveness of nasal ketamine therapy lies in its unique action on the brain compared to traditional antidepressants.

Targeting NMDA Receptors

Esketamine works on NMDA receptors that regulate glutamate, one of the brain’s most important neurotransmitters. By adjusting these pathways, treatment helps restore balance in brain activity linked to depression.

Enhancing Neuroplasticity

Spravato stimulates neuroplasticity, allowing the brain to form new, healthier neural connections. This makes it easier for patients to break away from entrenched patterns of negative thought and mood.

Faster Relief Than Oral Antidepressants

Most oral antidepressants take weeks to show benefits. By contrast, intranasal ketamine can produce measurable improvements in mood within hours to days.

Conditions Treated with Nasal Ketamine Therapy

Although ketamine spray therapy was developed for depression, ongoing research highlights its wider potential.

Treatment-Resistant Depression (TRD)

Spravato is FDA-approved for TRD, where patients have tried two or more antidepressants without success. For many, this option provides new hope and lasting relief.

Major Depressive Disorder with Suicidal Ideation

Patients with severe depressive symptoms, especially those with suicidal thoughts, can benefit from the rapid results of Spravato treatment.

Expanding Research in Anxiety and PTSD

While not FDA-approved for anxiety or post-traumatic stress disorder, clinical studies suggest promising results for these conditions.

Chronic Pain Applications

In specialized settings, intranasal ketamine has been studied for migraines, neuropathic pain, and other chronic conditions. These uses are considered off-label but demonstrate ketamine’s broad therapeutic potential.